From the Co-Chairs

Dear Colleague: Doug Dieterich and I would like to share with you an important activity relevant to infectious disease specialists treating patients with HCV and HIV/HCV coinfection. This special opportunity is a way to include the ID community in a discussion about emerging advances in the treatment of HCV infection. Regards, Mark S. Sulkowski, MD Infectious Disease Co-Host Douglas T. Dieterich, MD Infectious Disease Co-Host

Dear Colleague: Critical new information is available to help you improve clinical outcomes of treatment for your patients with hepatitis C virus (HCV) infection. You can participate in Achieving Optimum Outcomes: Customizing Treatment for Patients With HCV Infection, simply by viewing the webcast replay at your convenience over the next year. During this program, our panel of distinguished faculty will address the following issues: Using individualized therapy for HCV-infected patients rather than a "one-size-fits-all" approach The latest results from trials of pegylated formulations of interferon in combination with ribavirin or as monotherapy Practical strategies for immediately incorporating these up-to-date treatment methods into clinical practice Do not miss this opportunity to stay at the forefront of care. Please log on for this exciting program. Sincerely, Willis C. Maddrey, MD Co-Chair Eugene R. Schiff, MD Co-Chair

For questions or comments regarding this web site please contact: Webmaster